Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit ...
Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated contest for the biotech firm. The deal, finalized after Novo Nordisk withdrew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results